This article is from the WebMD News Archive
Are Breast Self-Exams Still a Valuable Tool?
March 17, 2004 (Hamburg, Germany) -- Most women have endured the lecture in a doctor's office on precisely how and how often they should conduct a breast self-examination (BSE). Many women have also felt guilty because they don't think they do BSE exactly right or often enough.
Now a study by Russian investigators, involving nearly 200,000 women, shows that the breast self-exam is not associated with reduced breast cancer mortality. However, some experts say that focusing on breast cancer mortality misses the point and overlooks its other benefits.
According to a study by Vladimir F. Semiglazov, MD, an oncologist at the N.N. Petrov Research Institute of Oncology in St. Petersburg, Russia, women who received intensive training in breast self-exams had similar rates of cancers diagnosed and deaths due to breast cancer as did women who received no training.
"The breast cancer mortality rate was not reduced in the group that received training in BSE," Lars Holmberg, MD, tells WebMD.
The study shows that we need more sensitive screening instruments, such as mammography to detect breast abnormalities, says Holmberg, who is a spokesman for the European Breast Cancer Conference and a professor of clinical cancer epidemiology at the Regional Oncological Center at Uppsala University Hospital in Uppsala, Sweden.
"However, it would be wrong to conclude that women should not be aware of their bodies and symptoms," he says.
Similar Rates of Cancer
Semiglazov's study looked at whether an intensive program of BSE instruction would reduce breast cancer mortality. Between 1985 and 1989, 96,000 women who were between 40 and 64 years old were taught BSE in intensive training sessions. A comparison group of women were given no instruction. For all women in the study, abnormalities on breast exams were biopsied, and the women were treated according to their diagnoses.
Among the women trained to do breast self-exams, 7,061 reported abnormalities, compared with 3,825 in the comparison group. The researchers found 1,032 benign (noncancerous) breast lesions in the BSE group and 547 in the comparison group.
But despite finding more abnormalities, the two groups had similar numbers of cancers diagnosed -- 733 and 702, respectively. Fifteen years after they were diagnosed with breast cancer, both groups had similar survival rates, 53.8% in the BSE group and 51.1% in the comparison group.
"We had a hope that in BSE we would have a low-tech screening method that would work in [countries] with limited resources, where mammography screening isn't feasible," Holmberg says. "Sadly, the results didn't show that BSE could be seen as a substitute."
Exam Still Useful
"A lot of people don't interpret correctly the results of this study and another study from China with similar results," Therese B. Bevers, MD, tells WebMD.

